这个有点类似张峰的专利，先是夺人眼球，最后一看专利旁落人家。

德国公司Forward Pharma 要横刀夺爱

In 2014, we made significant progress in advancing our intellectual property portfolio. The following summarizes the current status of several of our most important U.S. and European patents and patent applications.

• We are awaiting further action by the USPTO regarding our U.S. patent application No. 11/576,871. A USPTO examiner previously found our claims in this application directed to methods of treating MS using a daily 480 mg dose of DMF to be allowable and has recommended that an interference be declared against Biogen's U.S. patent No. 8,399,514.

• We have two pending U.S. patent applications relating to the 480 mg dose of DMF that we believe may soon be allowed, one of which (14/213,399) claims particular up-titration schedules of using DMF to treat MS, and the other of which (14/212,503) claims treating MS using particular compositions containing DMF and that also specifies levels of a DMF metabolite called mono methyl fumarate (MMF) in the bloodstream.

• Our erosion matrix patent issued on December 9, 2014 with patent number 8,906,420. This patent expires in January 2030 and covers the formulation of FP187.

• On November 18, 2014, we filed a lawsuit against Biogen alleging infringement of our German utility model. An oral proceeding in Germany is scheduled for February 16, 2016.

大家看一看全貌：

http://www.jefferies.com/CMSFiles/Jefferies.com/files/Foward%20Pharma.pdf